Navigation Links
Transplanted fatty livers associated with worse prognosis for patients with HCV
Date:1/13/2009

A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis). HCV recurrence was more frequent and earlier among those transplanted with such livers. These findings are in the January issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Recently, reports have revealed that survival rates among HCV-infected liver transplant recipients are decreasing. This is particularly troubling because HCV is the most common indication for liver transplantation in Western countries. In these places, the donor population is more likely to be overweight, and therefore more likely to have fatty livers. These organs are highly susceptible to cold or warm ischemia injury, leading researchers to hypothesize that liver steatosis may be affecting the outcomes for transplant recipients.

Researchers, led by Javier Briceo and Ruben Ciria of Cordoba, Spain, sought to determine the influence of donor liver steatosis on outcomes for HCV patients who received them. They included 120 patients who underwent liver transplantation as a result of HCV-cirrhosis between 1995 and 2005. Donor steatosis was categorized as absent (0-10 percent), mild (10-30 percent), moderate (30-60 percent) or severe (greater than 60 percent).

"Our results show a direct relationship between marginal donor, graft steatosis and a more frequent, severe and earlier viral recurrence after orthotopic liver transplantation for HCV-related cirrhosis," the authors report. Patient survival was significantly worse when graft steatosis was 30 percent or more.

Survival of the graft was inversely proportional to donor liver steatosis. After three years, graft survival was 72 percent for transplant recipients whose donor livers had no steatosis, 58 percent for mild, 43 percent for moderate and 42 percent for severe. The most profound decline in graft survival occurred when donor livers contained greater than 30 percent steatosis and were subjected to more than 12 hours of cold ischemic time.

The authors compared their results to outcomes of liver transplantations in individuals with alcohol-induced cirrhosis, as opposed to HCV. They found that donor steatosis greater than 30 percent did not reduce graft survival in these non-HCV patients.

"Further multicenter studies and a global consensus may be necessary to finally assess if the use of expanded criteria grafts is safe into HCV-positive recipients, as well as if nowadays the organ allocation system should need a change for this cohort of patients," they conclude.

An accompanying editorial by Mitchell Shiffman and Nevin Yilmaz of Virginia Commonwealth University Medical Center raises concerns about the study's conclusions. It points out that all patients did not undergo liver biopsies at specified time intervals, and there was not enough data on the patients with alcohol-induced cirrhosis to be sure that the populations were comparable.

Still, they were intrigued by the observation that the combination of donor graft steatosis and a prolongation in cold ischemic was associated with severe reperfusion injury.

"We strongly suggest that cold ischemia time should be limited when the donor graft contains greater than 30 percent steatosis and such grafts should only be utilized with caution for patients with chronic HCV," they conclude.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Circulating fats kill transplanted pancreas cells, study shows
2. Transplanted Bone Marrow Cells Aid Nerve Regeneration
3. Transplanted Liver Lining Cells May Cure Hemophilia
4. New approaches to protecting transplanted organs make first steps toward patients
5. Diet Change Can Curb Fatty Liver Disease
6. Attenuation of NASH by stimulation of free fatty acid metabolism
7. Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome
8. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
9. Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes
10. Dogs and Cats Need Omega-3 Fatty Acids Just as Humans Do - Nordic Naturals Offers Premium Fish Oil to Supplement Pets Diet!
11. Omega-3 Fatty Acids Wont Prevent Crohns Relapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... from Germany, announced it is bringing its product to the United States as part ... perfected over the last 25 years, Alcovit aims to reduce the productions of nasty ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology: